{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:52:21Z","timestamp":1784872341636,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"DOI":"10.1038\/s41366-026-02173-5","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:08:01Z","timestamp":1784261281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adopting the lancet commission definition of clinical obesity in metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-6123","authenticated-orcid":false,"given":"Karen Cheuk-Ying","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-7539","authenticated-orcid":false,"given":"Rex Wan-Hin","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor Kwan-Hung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-1126","authenticated-orcid":false,"given":"David Tak-Wai","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-3935","authenticated-orcid":false,"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2173_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Prim. 2025;11:14.","journal-title":"Nat Rev Dis Prim"},{"key":"2173_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156004","volume":"160","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, Henry L, Younossi ZM. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism. 2024;160:156004.","journal-title":"Metabolism"},{"key":"2173_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3350\/cmh.2022.0399","volume":"29","author":"RWH Hui","year":"2023","unstructured":"Hui RWH, Mak LY, Cheung TT, Lee VHF, Seto WK, Yuen MF. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2023;29:217\u201329.","journal-title":"Clin Mol Hepatol"},{"key":"2173_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"2173_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2173_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s13679-024-00580-1","volume":"13","author":"K Sweatt","year":"2024","unstructured":"Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward?. Curr Obes Rep. 2024;13:584\u201395.","journal-title":"Curr Obes Rep"},{"key":"2173_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diab Endocrinol. 2025;13:221\u201362.","journal-title":"Lancet Diab Endocrinol"},{"key":"2173_CR8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.apsb.2023.01.012","volume":"13","author":"X Jin","year":"2023","unstructured":"Jin X, Qiu T, Li L, Yu R, Chen X, Li C, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13:2403\u201324.","journal-title":"Acta Pharm Sin B"},{"key":"2173_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/jvh.13095","volume":"26","author":"LY Mak","year":"2019","unstructured":"Mak LY, Seto WK, Hui RWH, Fung J, Wong DKH, Lai CL, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat. 2019;26:818\u201327.","journal-title":"J Viral Hepat"},{"key":"2173_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1515\/hukin-2015-0063","volume":"47","author":"J Verney","year":"2015","unstructured":"Verney J, Schwartz C, Amiche S, Pereira B, Thivel D. Comparisons of a multi-frequency bioelectrical impedance analysis to the dual-energy X-ray absorptiometry scan in healthy young adults depending on their physical activity level. J Hum Kinet. 2015;47:73\u201380.","journal-title":"J Hum Kinet"},{"key":"2173_CR11","volume":"93","author":"MD Ballesteros-Pomar","year":"2022","unstructured":"Ballesteros-Pomar MD, Gonz\u00e1lez-Arn\u00e1iz E, Pintor-de-la Maza B, Barajas-Galindo D, Ariadel-Cobo D, Gonz\u00e1lez-Roza L, et al. Bioelectrical impedance analysis as an alternative to dual-energy x-ray absorptiometry in the assessment of fat mass and appendicular lean mass in patients with obesity. Nutr Burbank Los Angel Cty Calif. 2022;93:111442.","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"2173_CR12","doi-asserted-by":"crossref","unstructured":"WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet. 2004;363:157\u201363.","DOI":"10.1016\/S0140-6736(03)15268-3"},{"key":"2173_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KGMM Alberti","year":"2006","unstructured":"Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med J Br Diabet Assoc. 2006;23:469\u201380.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"2173_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2022.100078","volume":"77","author":"MA Amaral","year":"2022","unstructured":"Amaral MA, Mundstock E, Scarpatto CH, Ca\u00f1on-Monta\u00f1ez W, Mattiello R. Reference percentiles for bioimpedance body composition parameters of healthy individuals: a cross-sectional study. Clinics. 2022;77:100078.","journal-title":"Clinics"},{"key":"2173_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wong VWS, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","journal-title":"J Hepatol"},{"key":"2173_CR16","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc16-S005","volume":"39","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association2. Classification and diagnosis of diabetes. Diab Care. 2016;39:S13\u201322.","journal-title":"Diab Care"},{"key":"2173_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"2173_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21:241.","journal-title":"BMC Med Res Methodol"},{"key":"2173_CR19","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369.","journal-title":"N Engl J Med"},{"key":"2173_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","volume":"83","author":"G Issa","year":"2025","unstructured":"Issa G, Shang Y, Strandberg R, Hagstr\u00f6m H, Wester A. Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. J Hepatol. 2025;83:643\u201351.","journal-title":"J Hepatol"},{"key":"2173_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jhep.2025.01.014","volume":"83","author":"TCF Yip","year":"2025","unstructured":"Yip TCF, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304\u201314.","journal-title":"J Hepatol"},{"key":"2173_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/NSS.S468420","volume":"16","author":"L Wang","year":"2024","unstructured":"Wang L, Liu H, Zhou L, Zheng P, Li H, Zhang H, et al. Association of obstructive sleep apnea with nonalcoholic fatty liver disease: evidence, mechanism, and treatment. Nat Sci Sleep. 2024;16:917\u201333.","journal-title":"Nat Sci Sleep"},{"key":"2173_CR23","doi-asserted-by":"publisher","unstructured":"Beibei C., Junhai Z., Zongbiao T., Fang P. Obstructive sleep apnea and metabolic-associated fatty liver disease risk: Insights from National Health and Nutrition Examination Survey and Mendelian randomization analysis. Nutr Metab Cardiovasc Dis NMCD. 2025;104265. https:\/\/doi.org\/10.1016\/j.numecd.2025.104265.","DOI":"10.1016\/j.numecd.2025.104265"},{"key":"2173_CR24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/eurheartj\/ehl022","volume":"27","author":"MJ Domanski","year":"2006","unstructured":"Domanski MJ, Jablonski KA, Rice MM, Fowler SE, Braunwald E. PEACE Investigators. Obesity and cardiovascular events in patients with established coronary disease. Eur Heart J. 2006;27:1416\u201322.","journal-title":"Eur Heart J"},{"key":"2173_CR25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","volume":"43","author":"X Li","year":"2024","unstructured":"Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024;43:2005\u201316.","journal-title":"Clin Nutr"},{"key":"2173_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12072-025-10801-x","volume":"19","author":"MCC Cheah","year":"2025","unstructured":"Cheah MCC, Crane H, George J. Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis. Hepatol Int. 2025;19:607\u201318.","journal-title":"Hepatol Int"},{"key":"2173_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067.","journal-title":"JHEP Rep"},{"key":"2173_CR28","first-page":"2478","volume":"14","author":"T Sarkar Das","year":"2024","unstructured":"Sarkar Das T, Meng X, Abdallah M, Bilal M, Sarwar R, Shaukat A. An assessment of the feasibility, patient acceptance, and performance of point-of-care transient elastography for metabolic-dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Diagn Basel Switz. 2024;14:2478 .","journal-title":"Diagn Basel Switz"},{"key":"2173_CR29","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.jhep.2025.03.005","volume":"83","author":"LY Mak","year":"2025","unstructured":"Mak LY, Yip TCF, Lee CH, Lai JCT, Wong VWS. Underrepresentation of Asians in diagnostic test development and drug trials in MASLD. J Hepatol. 2025;83:e59\u201360.","journal-title":"J Hepatol"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02173-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:08:03Z","timestamp":1784261283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02173-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":29,"alternative-id":["2173"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02173-5","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MF Yuen is an advisory board member and\/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. WK Seto received speaker\u2019s fees from Echosesns, is an advisory board member and received speaker\u2019s fees of Abbott, received research funding from Astrazeneca, Alexion Pharmaceuticals, Boehringer Ingelheim, Pfizer and Ribo Life Science, and is an advisory board member, received speaker\u2019s fees and researching funding from Gilead Sciences. LY Mak received research grant support from Roche Diagnostics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study protocol conformed to the ethical guidelines of the 1975 Declarations of Helsinki. The study was approved by the Institutional Review Board of The University of Hong Kong \/ Hospital Authority Hong Kong West Cluster (HKU\/HA HKW IRB: reference number: UW 25-073, UW 22-006). Informed consent requirement was waived as the study was retrospective and observational in nature.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The abstract of this article has been presented at the following conference: (1) The Liver Meeting 2025 organized by the AASLD. The full article has not been published previously and is not under consideration for publication elsewhere. Its publication is approved by all authors and by the responsible authorities where the work was carried out. If accepted, this article will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.","order":3,"name":"Ethics","label":"Submission declaration","group":{"name":"EthicsHeading","label":"Ethics"}}]}}